WHWK

Whitehawk Therapeutics Inc (WHWK) Scenario Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Base Case

WHWK remains a low-valuation, financially liquid micro-cap with a very strong current ratio (17.4x) and net current asset value of about $181.3M.

TTM profitability remains weak with negative ROA (-41.2%), ROE (-53.9%), and ROIC (-47.0%), so the base case still depends on a turnaround rather than current earnings power.

Bull Case

A bull scenario is supported by the balance sheet cushion and asset coverage, with cash per share of $2.29 and tangible book value per share of $2.21.

If operating performance normalizes, the stock could re-rate from a depressed valuation base given the low enterprise value relative to assets.

Bear Case

The main downside remains continued operating losses and negative cash generation, as free cash flow yield is -26.3% and operating cash flow per share is -$0.84.

With margins still at 0% and solvency metrics weak, any delay in a turnaround could keep pressure on equity value despite the liquidity buffer.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Whitehawk Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →